Adalta Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Adalta Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-245	Closed	-$175K	–	106
2024 Q4	$175K	Hold	245	–	–	0.09%	75
2024 Q3	$258K	Hold	245	–	–	0.13%	68
2024 Q2	$258K	Hold	245	–	–	0.14%	67
2024 Q1	$236K	Hold	245	–	–	0.13%	67
2023 Q4	$215K	Hold	245	–	–	0.13%	67
2023 Q3	$202K	Buy	+245	New	+$193K	0.14%	64
2020 Q4	–	Sell	-342	Closed	-$191K	–	83
2020 Q3	$191K	Hold	342	–	–	0.14%	65
2020 Q2	$213K	Buy	+342	New	+$194K	0.17%	57

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adalta Capital Management's REGN Position: Q1 2025 in Review

Adalta Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 245 shares — an estimated $175K sold.

Adalta Capital Management first reported a position in REGN in Q2 2020 and held it in 8 quarters. The position peaked at $258K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Adalta Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Adalta Capital Management sold 245 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $175K.
Adalta Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Adalta Capital Management's Regeneron Pharmaceuticals position peaked at $258K in Q3 2024.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Adalta Capital Management's 13F filing for Q1 2025, filed 16 May 2025.